denodo_logo_over_white.png
Denodo Named a Leader in the 2024 Gartner® Magic Quadrant™ for Data Integration Tools for Five Consecutive Years
December 09, 2024 07:00 ET | Denodo Technologies Inc. (“Denodo”)
Denodo Named a Leader in the 2024 Gartner® Magic Quadrant™ for Data Integration Tools for Five Consecutive Years
Nusano.png
Nusano and GlyTherix Announce Lutetium-177 Supply Agreement
December 09, 2024 07:00 ET | Nusano, Inc.
VALENCIA, Calif. and SYDNEY, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Nusano, a physics company transforming the production of radioisotopes, and GlyTherix Ltd (GlyTherix), an Australian targeted...
logo.png
Next Hydrogen provides update on working capital debt financing
December 09, 2024 07:00 ET | Next Hydrogen Corporation
MISSISSAUGA, Ontario, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Next Hydrogen Solutions Inc. (“Next Hydrogen“) (TSXV:NXH, OTC:NXHSF), a designer and manufacturer of electrolyzers, is pleased to announce...
Seres Logo.png
FDA Grants Breakthrough Therapy Designation to Seres Therapeutics’ SER-155 for Reduction of Bloodstream Infections in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT)
December 09, 2024 07:00 ET | Seres Therapeutics, Inc.
Designation based on encouraging Phase 1b clinical data, including that SER-155 resulted in a 77% relative risk reduction in bacterial bloodstream infections versus placebo Breakthrough Therapy...
Western Investment Company Completes Series of Transactions to Shift its Focus to Property and Casualty Insurance and Investment Management
December 09, 2024 07:00 ET | The Western Investment Company of Canada
Western has completed the transactions announced on August 30, 2024 to shift Western’s focus to a P&C insurance and investment holding company.
coherent_logo_flat_ rgb_pos_blue.png
Coherent Signs Preliminary Memorandum of Terms With The U.S. Department of Commerce to Expand the World’s First 150 mm Indium Phosphide Manufacturing Line
December 09, 2024 07:00 ET | Coherent Corp.
SHERMAN, Texas, Dec. 09, 2024 (GLOBE NEWSWIRE) -- On Friday, December 5, 2024, it was announced that Coherent Corp. (NYSE: COHR), a leader in optoelectronic devices and technology, has signed a...
Z14UnD58_400x400.png
InspireMD Announces First Patient Enrolled in the CGUARDIANS II Pivotal Study of the CGuard Prime Carotid Stent System in Transcarotid Artery Revascularization Procedures (TCAR)
December 09, 2024 07:00 ET | InspireMD, Inc.
MIAMI, Dec. 09, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced that the first...
secura bio logo.png
New Combination Data of Secura Bio’s COPIKTRA® (duvelisib) Presented at the 2024 American Society of Hematology Meeting
December 09, 2024 07:00 ET | Secura Bio
Dr. Alison Moskowitz presented results of a Phase 1 study of combination duvelisib plus ruxolitinib in relapsed/refractory (R/R) peripheral T-cell lymphoma or cutaneous T-cell lymphoma Results...
Cogent_Biosciences_logo_RGB.png
Cogent Biosciences Announces Updated Clinical Results from SUMMIT, Showcasing Powerful Symptomatic Improvement in NonAdvanced Systemic Mastocytosis Patients
December 09, 2024 07:00 ET | Cogent Biosciences, Inc.
56% mean improvement in Total Symptom Score (TSS) at 24 weeks with 76% of patients achieving at least a 50% reduction in TSS                   89% of patients had >50% decrease in serum tryptase...
secura bio logo.png
Secura Bio Presented New Data from its Phase 2 PRIMO Trial of Copiktra® (Duvelisib) in Relapsed or Refractory Peripheral T-cell Lymphoma and Announced Plans for its Phase 3 TERZO Trial at the 2024 American Society of Hematology Meeting
December 09, 2024 07:00 ET | Secura Bio
Data from the Phase 2 PRIMO trial in 123 patients showed an overall response rate (ORR) of 48%, a complete response (CR) rate of 33%, and a median duration of response (DOR) of 7.89 months The...